Men Reason 5 O O
who Reason 5 O O
have Reason 5 O O
sex Reason 5 O O
with Reason 5 O O
men Reason 5 O O
(MSM) Reason 5 O O
living Reason 5 O O
with Reason 5 O O
HIV, Reason 5 O O
especially Reason 5 O O
those Reason 5 O O
who Reason 5 O O
are Reason 5 O O
young Reason 5 O O
or Reason 5 O O
who've Reason 5 O O
had Reason 5 O O
gonorrhea Reason 5 O O
should Reason 5 O O
get Reason 5 O O
the Reason 5 O O
human Reason 5 O O
papillomavirus Reason 5 O O
(HPV) Reason 5 O O
9-valent Reason 5 O O
vaccine Reason 5 O O
(Gardasil Reason 5 O O
9), Reason 5 O O
findings Reason 5 O O
of Reason 5 O O
a Reason 5 O O
[newly Reason 5 O O
published Reason 5 O O
study](https://journals.lww.com/jaids/Citation/2022/10010/Prevalence_and_Risk_Factors_of_Anal_HPV_Infection.16.aspx) Reason 5 O O
in Reason 5 O O
JAIDS Reason 5 O O
suggests. Reason 5 O O
According O O O O
to O O O O
the O O O O
World O O O O
Health O O O O
Organization, O O O O
[only O O O O
30%](https://www.who.int/news/item/31-10-2019-major-milestone-reached-as-100-countries-have-introduced-hpv-vaccine-into-national-schedule) O O O O
of O O O O
the O O O O
target O O O O
population O O O O
worldwide O O O O
has O O O O
received O O O O
the O O O O
HPV O O O O
vaccine. O O O O
Despite O O O O
increased O O O O
risk O O O O
for O O O O
HPV O O O O
anal O O O O
infection O O O O
(an O O O O
estimated O O O O
3 O O O O
out O O O O
of O O O O
4 O O O O
MSM O O O O
develop O O O O
an O O O O
anal O O O O
infection O O O O
from O O O O
any O O O O
HPV O O O O
genotype O O O O
in O O O O
their O O O O
lifetime, O O O O
epidemiological O O O O
studies O O O O
in O O O O
MSM O O O O
have O O O O
been O O O O
lacking, O O O O
leaving O O O O
gaps O O O O
in O O O O
data O O O O
in O O O O
terms O O O O
of O O O O
prevalence O O O O
rates O O O O
and O O O O
prevention. O O O O
To Reason 5 O O
help Reason 5 O O
characterize Reason 5 O O
which Reason 5 O O
MSM Reason 5 O O
subgroups Reason 5 O O
benefit Reason 5 O O
the Reason 5 O O
most Reason 5 O O
from Reason 5 O O
early Reason 5 O O
9-valent Reason 5 O O
HPV Reason 5 O O
vaccination, Reason 5 O O
researchers Reason 5 O O
from Reason 5 O O
Vita-Salute Reason 5 O O
San Reason 5 O O
Raffaele Reason 5 O O
University Reason 5 O O
in Reason 5 O O
Milan Reason 5 O O
determined Reason 5 O O
the Reason 5 O O
prevalence Reason 5 O O
of Reason 5 O O
anal Reason 5 O O
HPV Reason 5 O O
genotypes Reason 5 O O
in Reason 5 O O
MSM Reason 5 O O
who'd Reason 5 O O
been Reason 5 O O
living Reason 5 O O
with Reason 5 O O
HIV Reason 5 O O
for Reason 5 O O
5 Reason 5 O O
years, Reason 5 O O
and Reason 5 O O
they Reason 5 O O
analyzed Reason 5 O O
the Reason 5 O O
risk Reason 5 O O
factors Reason 5 O O
for Reason 5 O O
HPV Reason 5 O O
anal Reason 5 O O
infection. Reason 5 O O
Of O O O O
the O O O O
1352 O O O O
study O O O O
participants, O O O O
12% O O O O
were O O O O
not O O O O
infected O O O O
by O O O O
any O O O O
HPV O O O O
genotypes, O O O O
and O O O O
the O O O O
maximum O O O O
number O O O O
of O O O O
genotypes O O O O
infecting O O O O
one O O O O
person O O O O
— O O O O
6 O O O O
— O O O O
was O O O O
detected O O O O
in O O O O
0.4%(6) O O O O
people O O O O
The O O O O
prevalence O O O O
of O O O O
HR-HPV O O O O
genotypes O O O O
or O O O O
those O O O O
present O O O O
in O O O O
the O O O O
vaccine O O O O
remained O O O O
stable O O O O
over O O O O
time. O O O O
"Our Reason 5 O O
findings Reason 5 O O
suggest...that Reason 5 O O
all Reason 5 O O
MSM Reason 5 O O
with Reason 5 O O
HIV Reason 5 O O
would Reason 5 O O
benefit Reason 5 O O
from Reason 5 O O
Gardasil Reason 5 O O
9 Reason 5 O O
immunization, Reason 5 O O
particularly Reason 5 O O
the Reason 5 O O
youngest Reason 5 O O
and Reason 5 O O
those Reason 5 O O
with Reason 5 O O
a Reason 5 O O
prior Reason 5 O O
gonococcal Reason 5 O O
infection," Reason 5 O O
lead Reason 5 O O
study Reason 5 O O
author Reason 5 O O
Elena Reason 5 O O
Bruzzesi, Reason 5 O O
MD, Reason 5 O O
of Reason 5 O O
Vita-Salute Reason 5 O O
San Reason 5 O O
Raffaele Reason 5 O O
University Reason 5 O O
in Reason 5 O O
Milan, Reason 5 O O
and Reason 5 O O
her Reason 5 O O
co-authors Reason 5 O O
wrote. Reason 5 O O
To O O O O
determine O O O O
prevalence O O O O
of O O O O
HPV O O O O
genotypes O O O O
at O O O O
anal O O O O
sites O O O O
and O O O O
risk O O O O
factors, O O O O
the O O O O
authors O O O O
conducted O O O O
a O O O O
time-trend, O O O O
monocentric O O O O
study O O O O
on O O O O
participants O O O O
who O O O O
self-identified O O O O
as O O O O
MSM O O O O
who O O O O
engaged O O O O
in O O O O
anal O O O O
intercourse. O O O O
The O O O O
participants O O O O
underwent O O O O
one O O O O
or O O O O
more O O O O
anoscopies O O O O
for O O O O
HPV O O O O
genotyping O O O O
at O O O O
one O O O O
academic O O O O
hospital O O O O
in O O O O
Milan O O O O
between O O O O
2015 O O O O
and O O O O
2019. O O O O
Swab O O O O
specimens O O O O
were O O O O
collected O O O O
from O O O O
the O O O O
anal O O O O
canal O O O O
mucosa, O O O O
then O O O O
soaked O O O O
in O O O O
thin-layer O O O O
liquid O O O O
medium, O O O O
and O O O O
sent O O O O
for O O O O
molecular O O O O
analysis. O O O O
To O O O O
detect O O O O
HPV O O O O
phenotypes, O O O O
the O O O O
specimens O O O O
were O O O O
processed O O O O
by O O O O
multiplex O O O O
real-time O O O O
polymerase O O O O
chain O O O O
reaction. O O O O
Findings O O O O
showed O O O O
that: O O O O
The O O O O
overall O O O O
prevalence O O O O
of O O O O
MSM O O O O
with O O O O
at O O O O
least O O O O
1 O O O O
anal O O O O
HPV O O O O
genotype O O O O
was O O O O
88%, O O O O
with O O O O
prevalence O O O O
ranging O O O O
from O O O O
77% O O O O
to O O O O
84%, O O O O
and O O O O
no O O O O
trend O O O O
difference O O O O
over O O O O
the O O O O
5-year O O O O
period. O O O O
79% O O O O
of O O O O
participants O O O O
were O O O O
exposed O O O O
to O O O O
at O O O O
least O O O O
1 O O O O
high-risk O O O O
(HR)-HPV O O O O
genotype, O O O O
and O O O O
67.4% O O O O
by O O O O
at O O O O
least O O O O
1 O O O O
low-risk O O O O
in O O O O
27%, O O O O
was O O O O
the O O O O
most O O O O
prevalent O O O O
11, O O O O
16, O O O O
and O O O O
18 O O O O
prevalence O O O O
was O O O O
22%, O O O O
13%, O O O O
23%, O O O O
and O O O O
11%, O O O O
respectively. O O O O
Of O O O O
the O O O O
HR O O O O
genotypes, O O O O
HPV-16 O O O O
and O O O O
HPV-18 O O O O
are O O O O
most O O O O
often O O O O
linked O O O O
with O O O O
squamous O O O O
cell O O O O
cancers O O O O
and O O O O
adenocarcinomas, O O O O
and O O O O
in O O O O
the O O O O
study, O O O O
prevalence O O O O
did O O O O
not O O O O
change O O O O
over O O O O
time. O O O O
71% O O O O
of O O O O
participants O O O O
carried O O O O
at O O O O
least O O O O
1 O O O O
genotype O O O O
covered O O O O
by O O O O
the O O O O
vaccine, O O O O
with O O O O
no O O O O
change O O O O
over O O O O
time. O O O O
On O O O O
multivariable O O O O
analysis, O O O O
the O O O O
risk O O O O
of O O O O
carrying O O O O
at O O O O
least O O O O
1 O O O O
high-risk O O O O
HPV O O O O
genotype O O O O
was O O O O
linked O O O O
with O O O O
younger O O O O
age O O O O
(adjusted O O O O
odds O O O O
ratio O O O O
[aOR] O O O O
for O O O O
30 O O O O
years O O O O
or O O O O
younger O O O O
compared O O O O
with O O O O
older O O O O
than O O O O
45 O O O O
years O O O O
2.714; O O O O
95% O O O O
confidence O O O O
interval O O O O
[CI], O O O O
1.100 O O O O
4.078). O O O O
Also O O O O
on O O O O
multivariable O O O O
analysis, O O O O
the O O O O
risk O O O O
of O O O O
having O O O O
one O O O O
or O O O O
more O O O O
genotypes O O O O
targeted O O O O
by O O O O
the O O O O
9-valent O O O O
vaccine O O O O
was O O O O
linked O O O O
with O O O O
younger O O O O
age O O O O
(aOR, O O O O
1.868; O O O O
95% O O O O
1.056 O O O O
3.018). O O O O
The O O O O
Safe, O O O O
and O O O O
Underutilized O O O O
"We Reason 5 O O
are Reason 5 O O
underutilizing Reason 5 O O
the Reason 5 O O
HPV Reason 5 O O
vaccine Reason 5 O O
in Reason 5 O O
our Reason 5 O O
clinical Reason 5 O O
settings Reason 5 O O
in Reason 5 O O
the Reason 5 O O
United Reason 5 O O
States Reason 5 O O
and Reason 5 O O
globally," Reason 5 O O
Mehri Reason 5 O O
S. Reason 5 O O
McKellar, Reason 5 O O
MD, Reason 5 O O
an Reason 5 O O
infectious Reason 5 O O
disease Reason 5 O O
specialist Reason 5 O O
at Reason 5 O O
Duke Reason 5 O O
Health Reason 5 O O
in Reason 5 O O
Durham, Reason 5 O O
North Reason 5 O O
Carolina, Reason 5 O O
told Reason 5 O O
Medscape Reason 5 O O
Medical Reason 5 O O
News Reason 5 O O
by Reason 5 O O
email. Reason 5 O O
"This Reason 5 O O
powerful Reason 5 O O
study Reason 5 O O
provides Reason 5 O O
important Reason 5 O O
data Reason 5 O O
on Reason 5 O O
HPV Reason 5 O O
genotype Reason 5 O O
prevalence Reason 5 O O
in Reason 5 O O
the Reason 5 O O
MSM Reason 5 O O
HIV+ Reason 5 O O
population, Reason 5 O O
validating Reason 5 O O
that Reason 5 O O
Gardasil Reason 5 O O
9 Reason 5 O O
will Reason 5 O O
greatly Reason 5 O O
help Reason 5 O O
these Reason 5 O O
individuals," Reason 5 O O
said Reason 5 O O
McKellar, Reason 5 O O
who O O O O
was O O O O
not O O O O
involved O O O O
in O O O O
the O O O O
study. O O O O
Robert O O O O
Salata, O O O O
MD, O O O O
infectious O O O O
disease O O O O
specialist O O O O
and O O O O
professor O O O O
at O O O O
Case O O O O
Western O O O O
Reserve O O O O
University O O O O
School O O O O
of O O O O
Medicine O O O O
in O O O O
Cleveland, O O O O
Ohio, O O O O
also O O O O
encourages O O O O
MSM O O O O
to O O O O
get O O O O
the O O O O
vaccine. O O O O
"It Reason 5 O O
is Reason 5 O O
important Reason 5 O O
to Reason 5 O O
understand Reason 5 O O
that Reason 5 O O
the Reason 5 O O
prevalence Reason 5 O O
of Reason 5 O O
anal Reason 5 O O
HPV Reason 5 O O
in Reason 5 O O
men Reason 5 O O
who Reason 5 O O
have Reason 5 O O
sex Reason 5 O O
with Reason 5 O O
men Reason 5 O O
is Reason 5 O O
very Reason 5 O O
high, Reason 5 O O
that Reason 5 O O
the Reason 5 O O
prevalence, Reason 5 O O
including Reason 5 O O
high-risk Reason 5 O O
genotypes, Reason 5 O O
has Reason 5 O O
remained Reason 5 O O
stable, Reason 5 O O
and Reason 5 O O
that Reason 5 O O
the Reason 5 O O
9-valent Reason 5 O O
vaccine Reason 5 O O
is Reason 5 O O
clearly Reason 5 O O
indicated, Reason 5 O O
especially Reason 5 O O
in Reason 5 O O
younger Reason 5 O O
men Reason 5 O O
and Reason 5 O O
those Reason 5 O O
with Reason 5 O O
known Reason 5 O O
gonorrhea Reason 5 O O
and Reason 5 O O
other Reason 5 O O
STDs," Reason 5 O O
Salata Reason 5 O O
(who Reason 5 O O
was Reason 5 O O
also Reason 5 O O
not Reason 5 O O
involved Reason 5 O O
in Reason 5 O O
the Reason 5 O O
study) Reason 5 O O
said Reason 5 O O
by Reason 5 O O
email. Reason 5 O O
"This Reason 5 O O
is Reason 5 O O
an Reason 5 O O
important Reason 5 O O
reminder Reason 5 O O
for Reason 5 O O
us Reason 5 O O
to Reason 5 O O
continue Reason 5 O O
promoting Reason 5 O O
and Reason 5 O O
providing Reason 5 O O
the Reason 5 O O
vaccine Reason 5 O O
to Reason 5 O O
our Reason 5 O O
patients, Reason 5 O O
especially Reason 5 O O
to Reason 5 O O
HIV+ Reason 5 O O
men Reason 5 O O
who Reason 5 O O
have Reason 5 O O
sex Reason 5 O O
with Reason 5 O O
men, Reason 5 O O
who Reason 5 O O
have Reason 5 O O
the Reason 5 O O
highest Reason 5 O O
rates Reason 5 O O
of Reason 5 O O
anal Reason 5 O O
infection Reason 5 O O
with Reason 5 O O
HPV," Reason 5 O O
McKellar Reason 5 O O
advised. Reason 5 O O
The O O O O
authors, O O O O
McKellar, O O O O
and O O O O
Salata O O O O
report O O O O
no O O O O
relevant O O O O
financial O O O O
relationships. O O O O
Funding O O O O
information O O O O
was O O O O
not O O O O
provided. O O O O
J O O O O
Acquir O O O O
Immune O O O O
Defic O O O O
Syndr. O O O O
Published O O O O
online O O O O
October O O O O
1, O O O O
2022. O O O O
[Abstract](https://journals.lww.com/jaids/Citation/2022/10010/Prevalence_and_Risk_Factors_of_Anal_HPV_Infection.16.aspx) O O O O
Credits: O O O O
Lead O O O O
image: O O O O
E+ O O O O
/ O O O O
Getty O O O O
Images O O O O
Image O O O O
1: O O O O
Duke O O O O
Health O O O O
Image O O O O
2: O O O O
Case O O O O
Western O O O O
Reserve O O O O
University O O O O
Medscape O O O O
Medical O O O O
News O O O O
© O O O O
2022 O O O O
WebMD, O O O O
LLC O O O O
Send O O O O
news O O O O
tips O O O O
to O O O O
[news@medscape.net](mailto:news@medscape.net). O O O O
Cite O O O O
this: O O O O
Gardasil O O O O
9 O O O O
HPV O O O O
Vaccine O O O O
Advised O O O O
for O O O O
MSM O O O O
